OGN

NEUTRALM&A

Organon & Co.

2026-07-13

Price

$13.50

-0.15%

This is the 2026-07-13 snapshot — the signals and analysis for OGN as of this single trading day.

View full OGN research hub →

Score12.5Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.5xvs 20d avg

Analysis

Organon's price action is entirely dictated by its pending acquisition by Sun Pharma for $14.00 per share in cash, explaining the stock's complete indifference to current geopolitical turbulence. The technical signals—specifically QUIET_STORM and STEADY_CLIMB—perfectly capture this M&A arbitrage dynamic, reflecting steady institutional accumulation and structurally suppressed volatility. Within the current RISK_ON (GEOPOLITICAL) regime, OGN serves as an insulated safe haven, where buyers are confidently absorbing shares to capture the remaining $0.50 spread ahead of the expected early 2027 deal close.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKSELLER FATIGUE

Key Takeaways

M&A Arbitrage Anchor: The pending $14.00 per share all-cash buyout by Sun Pharma fundamentally caps upside while providing a hard fundamental floor near current prices.
Macro Insulation: OGN's tight trading range and low volatility offer a high-conviction defensive posture against the escalating U.S.-Iran conflict.
Key Risk: Regulatory pushback or financing hurdles for Sun Pharma are the only structural threats to the remaining arbitrage spread.

← Back to 2026-07-13 View Full OGN History →Yahoo Finance &nearr;